# A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

> **NCT00623870** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 116 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** RO5045337

## Key facts

- **NCT ID:** NCT00623870
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623870, "A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00623870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*